TTPH - Tetraphase Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 1.93
52-Week Change 3-90.37%
S&P500 52-Week Change 37.98%
52 Week High 349.60
52 Week Low 33.36
50-Day Moving Average 35.20
200-Day Moving Average 311.77

Share Statistics

Avg Vol (3 month) 359.22k
Avg Vol (10 day) 3128.2k
Shares Outstanding 52.72M
Float 2.7M
% Held by Insiders 10.61%
% Held by Institutions 145.24%
Shares Short (Sep 30, 2019) 454.79k
Short Ratio (Sep 30, 2019) 40.83
Short % of Float (Sep 30, 2019) 42.04%
Short % of Shares Outstanding (Sep 30, 2019) 42.02%
Shares Short (prior month Aug 30, 2019) 448.31k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 220/1
Last Split Date 3Sep 27, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-1,067.16%

Management Effectiveness

Return on Assets (ttm)-48.99%
Return on Equity (ttm)-109.46%

Income Statement

Revenue (ttm)7.78M
Revenue Per Share (ttm)2.90
Quarterly Revenue Growth (yoy)-90.70%
Gross Profit (ttm)-36.1M
EBITDA -82.29M
Net Income Avi to Common (ttm)-83.45M
Diluted EPS (ttm)-31.10
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)70.95M
Total Cash Per Share (mrq)26.13
Total Debt (mrq)34.43M
Total Debt/Equity (mrq)82.49
Current Ratio (mrq)4.10
Book Value Per Share (mrq)15.37

Cash Flow Statement

Operating Cash Flow (ttm)-66.19M
Levered Free Cash Flow (ttm)-42.18M